Orchestra BioMed (OBIO) Stock Price, News & Analysis

Company Overview

Orchestra BioMed is a medical technology company that develops therapies for cardiovascular and other diseases, often in collaboration with established medical-device companies. Its work focuses on technologies intended to integrate with existing treatment approaches and devices.

The company’s lead program, AVIM therapy, is designed to lower blood pressure in people with pacemakers by adjusting the timing of cardiac pacing. Orchestra BioMed is also developing Virtue SAB, a drug-delivery balloon intended to treat coronary artery disease by delivering sirolimus to blood vessels.

Founded in 2018 and based in New Hope, Pennsylvania, Orchestra BioMed has formed strategic collaborations to advance its technologies, including agreements with Medtronic related to AVIM therapy. David Hochman serves as the company’s chairman and chief executive officer.

Key Stats

• Today's Range: $6.00 to $7.37
• 50-Day Range: $5.08 to $7.25
• 52-Week Range: $3.46 to $7.37
• Volume: 1.57 million shs
• Average Volume: 483,382 shs
• Market Capitalization: $445.51 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.29
• Consensus Rating: Moderate Buy

Orchestra BioMed Stock Analysis - MarketRank™

Orchestra BioMed scored higher than 85% of companies evaluated by MarketBeat, and ranked 64th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Orchestra BioMed has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 7 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Orchestra BioMed has a consensus price target of $13.29, representing about 83.3% upside from its current price of $7.25.

Amount of Analyst Coverage

Orchestra BioMed has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Orchestra BioMed are expected to grow in the coming year, from ($1.53) to ($1.45) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Orchestra BioMed is -9.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Orchestra BioMed is -9.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Orchestra BioMed has a P/B Ratio of 55.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.81% of the float of Orchestra BioMed has been sold short.

Short Interest Ratio / Days to Cover

Orchestra BioMed has a short interest ratio ("days to cover") of 6.99.

Change versus previous month

Short interest in Orchestra BioMed has recently increased by 7.03%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Orchestra BioMed does not currently pay a dividend.

Dividend Growth

Orchestra BioMed does not have a long track record of dividend growth.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 1.05

News Sentiment

Orchestra BioMed has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 19 news articles for Orchestra BioMed this week, compared to 3 articles on an average week.

Search Interest

1 people have searched for OBIO on MarketBeat in the last 30 days.

Company Ownership

• Score: 3.8 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

5 insiders have purchased shares of Orchestra BioMed in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $32,960.00 in company stock, which represents 0.0074% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Orchestra BioMed insiders have bought 12.90% more of their company's stock than they have sold. Specifically, they have bought $288,560.00 in company stock and sold $255,600.00 in company stock.

Percentage Held by Insiders

7.50% of the stock of Orchestra BioMed is held by insiders.

Percentage Held by Institutions

53.20% of the stock of Orchestra BioMed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/10/2026
• Today: 11/15/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:OBIO
• CIK: 1814114
• Web: orchestrabiomed.com
• Phone: (646) 343-9298
• Fax: N/A
• Employees: 86
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Orchestra BioMed: $13.29
• High Price Target: $20.00
• Low Price Target: $10.00
• Potential Upside/Downside: +83.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.75)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$52.70 million
• Net Margins: -182.50%
• Pretax Margin: -182.50%
• Return on Equity: -186.93%
• Return on Assets: -51.90%

Debt

• Debt-to-Equity Ratio: 4.58
• Current Ratio: 7.25
• Quick Ratio: 8.24

Sales & Book Value

• Annual Sales: $33.48 million
• Price / Sales: 13.31
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.13 per share
• Price / Book: 55.77

Miscellaneous

• Outstanding Shares: 61,450,000
• Free Float: 56,844,000
• Market Cap: $445.51 million
• Optionable: Optionable
• Beta: 0.56